Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis.
TL;DR
The prognostic factors identified in this meta-analysis should be considered as part of risk stratification frameworks for anticoagulation management in patients with cancer and VTE.
📈 연도별 인용 (2025–2026) · 합계 11
OpenAlex 토픽 ·
Venous Thromboembolism Diagnosis and Management
Atrial Fibrillation Management and Outcomes
Central Venous Catheters and Hemodialysis
The prognostic factors identified in this meta-analysis should be considered as part of risk stratification frameworks for anticoagulation management in patients with cancer and VTE.
- 표본수 (n) 96
- 95% CI 1.08-2.09
- 연구 설계 systematic review
APA
Faizan Khan, Tobias Tritschler, et al. (2026). Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis.. European heart journal, 47(16), 1917-1929. https://doi.org/10.1093/eurheartj/ehaf453
MLA
Faizan Khan, et al.. "Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis.." European heart journal, vol. 47, no. 16, 2026, pp. 1917-1929.
PMID
40579365
Abstract
[BACKGROUND AND AIMS] Patients with cancer and venous thromboembolism (VTE) have a high risk of recurrent VTE and anticoagulant-related bleeding. This study aimed to identify prognostic factors for these complications.
[METHODS] A systematic review was performed for randomized trials and cohort studies evaluating prognostic factors for recurrent VTE or anticoagulant-related bleeding in adult patients with cancer and VTE. Adjusted hazard ratios (aHRs) for factors were pooled using random-effects meta-analysis. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach.
[RESULTS] Thirty-three studies (n = 96 753) were included in the meta-analyses. Factors with high certainty of association with increased risk of recurrent VTE included a previous history of VTE [aHR 1.50 (95% CI 1.08-2.09)], Eastern Cooperative Oncology Group (ECOG) performance status >0 [1.81 (1.34-2.46)] or >1 [2.44 (1.55-3.84)], advanced cancer [1.38 (1.15-1.65)], and specific cancer sites including lung [1.78 (1.29-2.46)], hepatobiliary [2.37 (1.70-3.30)], pancreas [3.20 (2.06-4.96)], and genitourinary [1.38 (1.14-1.67)]. Conversely, recent surgery [aHR 0.56 (95% CI 0.40-0.76)] and breast cancer [0.43 (0.23-0.81)] had a high certainty of association with a decreased risk. Factors with a high certainty of association with an increased risk of anticoagulant-related bleeding included a history of bleeding [aHR 2.41 (95% CI 1.50-3.88)], ECOG performance status ≥2 [2.10 (1.48-2.99)], advanced cancer [1.60 (1.29-1.97)], and cancers of the brain [2.25 (1.64-3.09)], gastrointestinal system [1.74 (1.44-2.11)], genitourinary system [1.90 (1.48-2.45)], and prostate [1.72 (1.26-2.34)].
[CONCLUSIONS] The prognostic factors identified in this meta-analysis should be considered as part of risk stratification frameworks for anticoagulation management in patients with cancer and VTE.
[METHODS] A systematic review was performed for randomized trials and cohort studies evaluating prognostic factors for recurrent VTE or anticoagulant-related bleeding in adult patients with cancer and VTE. Adjusted hazard ratios (aHRs) for factors were pooled using random-effects meta-analysis. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach.
[RESULTS] Thirty-three studies (n = 96 753) were included in the meta-analyses. Factors with high certainty of association with increased risk of recurrent VTE included a previous history of VTE [aHR 1.50 (95% CI 1.08-2.09)], Eastern Cooperative Oncology Group (ECOG) performance status >0 [1.81 (1.34-2.46)] or >1 [2.44 (1.55-3.84)], advanced cancer [1.38 (1.15-1.65)], and specific cancer sites including lung [1.78 (1.29-2.46)], hepatobiliary [2.37 (1.70-3.30)], pancreas [3.20 (2.06-4.96)], and genitourinary [1.38 (1.14-1.67)]. Conversely, recent surgery [aHR 0.56 (95% CI 0.40-0.76)] and breast cancer [0.43 (0.23-0.81)] had a high certainty of association with a decreased risk. Factors with a high certainty of association with an increased risk of anticoagulant-related bleeding included a history of bleeding [aHR 2.41 (95% CI 1.50-3.88)], ECOG performance status ≥2 [2.10 (1.48-2.99)], advanced cancer [1.60 (1.29-1.97)], and cancers of the brain [2.25 (1.64-3.09)], gastrointestinal system [1.74 (1.44-2.11)], genitourinary system [1.90 (1.48-2.45)], and prostate [1.72 (1.26-2.34)].
[CONCLUSIONS] The prognostic factors identified in this meta-analysis should be considered as part of risk stratification frameworks for anticoagulation management in patients with cancer and VTE.
MeSH Terms
Humans; Neoplasms; Venous Thromboembolism; Anticoagulants; Recurrence; Hemorrhage; Risk Factors; Prognosis; Female; Randomized Controlled Trials as Topic; Male; Adult
같은 제1저자의 인용 많은 논문 (5)
- EPR26-173: Weekend Admissions and Clinical Outcomes in Pancreatic Cancer: Evidence From the National Inpatient Sample.
- Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer.
- Bioinformatics Approaches in Noncoding RNAs Research.
- Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis.
- CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis.